Scrutinizing FDA Drug Approvals (The Motley Fool)
The pace has certainly slowed since the Vioxx recall.

Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program (PR Newswire via Yahoo! Finance)
Amarin Corporation plc today announced that management has met with the U.S. Food and Drug Administration following the completion of a comprehensive data review from its large-scale Phase III studies of Miraxion to treat Huntington's disease .